Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2026-04-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（庄学敏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the director's duties, attendance at board and committee meetings, review of financial reports, communication with auditors, and oversight activities during the year. The content focuses on the director's role, compliance with laws and regulations, and evaluation of company governance and financial reporting. It is not a full annual report or financial statement but a detailed management/board-related report on the independent director's activities and oversight for the year. This fits the category of Board/Management Information (MANG), which includes announcements about board activities and management information. The document length (6249 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2026-04-27 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal control over financial reporting for the fiscal year ending December 31, 2025. The content includes the auditor's responsibility, the company's responsibility, and the auditor's opinion on internal control effectiveness. The document is 3178 characters long, which is relatively short but contains the full audit report text rather than just an announcement or certification. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) or Interim Report (IR) because it focuses solely on internal control audit results. It is not a Regulatory Filing (RNS) because it contains substantive audit content, not just certification or attestation. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-27 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangdong Yongshun Biological Pharmaceutical Co., Ltd. regarding the acquisition of a new veterinary drug registration certificate. It details the approval by the Ministry of Agriculture and Rural Affairs of China for a new vaccine product, including product information, regulatory background, and potential impact on the company. The document is short (1261 characters) and serves as a regulatory announcement about a new product approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-25 Chinese
2025 年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025 年年度业绩快报公告" which translates to "2025 Annual Performance Express Announcement" or "Annual Earnings Quick Report Announcement." It contains preliminary financial data for the full year 2025, including revenue, net profit, and other key financial metrics. The text explicitly states that the data are preliminary and unaudited, and the final audited data will be disclosed in the company's full 2025 Annual Report. The document is relatively short (1813 characters) and serves as a quick summary or earnings preview rather than a full comprehensive annual report. It also includes a risk warning about the preliminary nature of the data and refers investors to the forthcoming full annual report for detailed audited information. This type of document aligns with an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full detailed report. Therefore, the correct classification is Earnings Release (ER). FY 2025
2026-02-25 Chinese
关于完成注销子公司的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the completion of the deregistration (cancellation) of its subsidiary, Guangdong Yongshun Bioengineering Co., Ltd. It includes details about the subsidiary, the reason for deregistration, and the impact on the company. The document is short (882 characters) and is a formal announcement about a corporate structural change rather than a financial report or detailed management discussion. It does not contain financial statements, audit information, or regulatory certifications. It is not a report publication announcement since it contains substantive content about the deregistration event itself. The content fits best under a regulatory announcement category related to corporate structural changes but does not match categories like MANG (management changes) or SHA (share capital changes). The closest fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-12-21 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2025 Third Quarter Report" of Guangdong Yongshun Biopharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the period ending September 30, 2025. The report explicitly states it is a quarterly report and includes comprehensive financial statements and management commentary. It is unaudited but contains substantive financial data and analysis for the quarter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.